Pancreatic Enzyme Replacement Therapy (PERT) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Trial Profile

Pancreatic Enzyme Replacement Therapy (PERT) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Pancrelipase (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 07 Jun 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 28 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top